1 February 2023 - The February 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect.

There are a few new/revised listings of note in the Community Schedule this month.

• Adrenaline (EpiPen, EpiPen Jr) - new formulation
• Infliximab (Remicade) - restriction change
• Ustekinumab (Stelara) - new indications (Crohn's disease, ulcerative colitis)
• Vedolizumab (Entyvio) - new indications (Crohn's disease, ulcerative colitis)

Read New Zealand Pharmaceutical Schedule update